New cocktail of drugs shows promise for tough lung cancer
NCT ID NCT04837716
First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This early-phase trial is testing a combination of four drugs—ensartinib, two chemotherapy drugs, and a targeted antibody—in 12 people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the combination controls the disease. It is a small, first-in-human study to check for side effects and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ensartinib, carboplatin, pemetrexed, and bevacizumab
- What this could lead to
- If successful, this could lead to a more effective combination therapy for ALK-positive lung cancer that has spread or come back.
- What could go wrong
- This is a very early, small phase 1 trial with only 12 participants, so results may not apply to all patients. Side effects from combining these drugs are unknown and could be severe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Could a muscle relaxant help fight lung cancer? scientists test papaverine with standard therapy
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
- New drug combo shows promise for tough cancers